ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

cabozantinib

Also written as “Cabozantinib”, “XL184” and “Cabozantinib tablets”.

Its studies are mostly in Neoplasms · Carcinoma, Renal Cell · Prostatic Neoplasms · Carcinoma, Hepatocellular · Glioblastoma, led by 5 companies.

Drug pageCabozantinib: every studyMany companies study it; this page follows only the 33 they lead. All 223 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jul 8, 201333 company-led studies, 8 open or runningNext primary completion: Aug 25, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Exelixisits history only237 open or runningphase 4since Jul 8, 2013Sep 20, 2005May 31, 2030phase 3 · NCT07620574
Bristol-Myers Squibb51 open or runningphase 3since May 3, 2017Nov 24, 2009Aug 25, 2029phase 2 · NCT03899155
Ipsenits history only20 open or runningphase 2since May 9, 2019May 9, 2019none ahead
Takedaits history only20 open or runningphase 2since Nov 8, 2017Nov 8, 2017none ahead
Academic Thoracic Oncology Medical Investigators Consortiumits history only10 open or runningphase 2since Apr 23, 2018Apr 23, 2018none ahead

Also a collaborator on its studies: Novartis, Clovis Oncology, Johnson & Johnson, Ono Pharmaceutical, Roche-Genentech and Eli Lilly.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bristol-Myers Squibb only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 24, 2009First study: phase 1 study in NeoplasmsFirst studyNCT01018745 · 3 enrolled · Japan
  2. Aug 3, 2012Phase 2 study in Carcinoma, HepatocellularNCT01658878 · 657 enrolled · United States, Canada, France and more
  3. May 3, 2017Phase 3 study in Carcinoma, Renal CellNCT03141177 · 701 enrolled · United States, Argentina, Australia and more
  4. Apr 1, 2019Phase 2 study in NeoplasmsNCT03899155 · 1,500 planned · United States, Argentina, Australia and more
  5. Nov 1, 2019Phase 2 study in CarcinomaNCT04151563 · United States, Argentina, Belgium and more

Ahead

  1. Aug 25, 2029Primary completion: phase 2 study in NeoplasmsNCT03899155

TargetBeta

KDR →MET →read by rule
“Vascular endothelial growth factor receptor 2 inhibitor; Hepatocyte growth factor receptor inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
zanzalintinibruleExelixisphase 317

Studies

All 5 Bristol-Myers Squibb leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04151563Carcinoma · United States, Argentina, Belgium and more2WithdrawnDec 17, 20230
NCT03899155Neoplasms · United States, Argentina, Australia and more2RecruitingAug 25, 20291,500
NCT03141177Carcinoma, Renal Cell · United States, Argentina, Australia and more3CompletedFeb 12, 2020701
NCT01658878Carcinoma, Hepatocellular · United States, Canada, France and more2CompletedNov 12, 2024657
NCT01018745Neoplasms · Japan1CompletedJul 20103

How it is read

Names in the registry

  • “Cabozantinib”, 18 entries
  • “cabozantinib”, 9 entries
  • “XL184”, 6 entries
  • “Cabozantinib tablets”, 2 entries
  • “Cabozantinib (XL184) 140 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.